CAR-T therapy

check

Complete Inflammatory Picture

Enables testing of key biomarkers essential for cytokine release syndrome (CRS) assessment including IL-1.

nest_clock_farsight_analog

Fast Results = Better Outcomes

60-minute turnaround time on the Evidence MultiSTAT compared with 3–4 hours via laboratory methods.

target

Precision Treatment Decisions

Rapid cytokine results allow clinicians to immediately determine appropriate treatment options for patients. This precision saves lives—and prevents unnecessary treatments.

handshake

Real-Time Decision Support

Supports critical decisions in managing CRS and ICANS.

clinical_notes

Improved Clinical Efficiency

Shorter stays, fewer escalations, earlier interventions in real-time.

shield_with_heart

Proven Reliability

Used in advanced research settings and now deployed in UK frontline clinical care

The MultiSTAT Hyperinflammation Biochip revolutionises the clinical pathway by delivering rapid, comprehensive cytokine profiling directly within hospital and critical care settings. By delivering the right cytokine data at the right time, clinicians can act faster, personalise treatment, and prevent life-threatening complications. The MultiSTAT Hyperinflammation Biochip isn't just faster testing - it's a fundamental shift in how hospitals manage CAR-T patients.

Hyperinflammation Biochip
IL-1β	IL-6	TNF-α
IL-15	IL-2	IFN-γ
MCP-1	Ferritin	D-Dimer

The Challenge: Slow, Incomplete Biomarker Testing for CAR‑T Patients

CAR-T recipients are at high risk of developing Cytokine Release Syndrome (CRS)—a life-threatening complication requiring rapid intervention.

However, current hospital laboratory workflows present major challenges:

Long Turnaround Times

Traditional lab-based methods take 3-4 hours and often require batching
Not suitable for hour-by-hour management of CRS

Limited Biomarker Availability

Most hospital labs cannot test IL-1, a critical marker in determining whether inflammation is IL‑1 or IL-6 mediated
IL-1 testing often requires referral to specialist external labs
Delays lead to slower treatment decisions and risk of rapid patient deterioration

Extended Hospital Stays

Patients remain in hospital for 12 days “just in case”, due to the risk of delayed-onset CRS
Results frequently arrive too late to influence early intervention, increasing risks and costs

Clinical Pathway Integration: Fast, Frequent Monitoring

The MultiSTAT Hyperinflammation Biochip can be used at key stages of the CAR T journey:

Before CAR T Infusion

Establish inflammatory baseline levels

Days 0, 1, 2 Post Infusion

Frequent biomarker monitoring detects early signs of CRS
CRS most commonly emerges within the first 48 hours

First Week Post Infusion

Track response to supportive care, steroids, Anakinra, or Tocilizumab

Up to 14 Days Post Infusion

Monitor recovery, detect complications, and confirm remission of inflammation

Evidence MultiSTAT

Easy to use, small footprint analyser facilitating multiplex detection of up to 48 targets from a single patient sample.

Complete with large, touch screen display allowing the operator to easily navigate through the software and view results.

Within the drawer there are two compartments one for the reagent cartridge and one for the tip cartridge. The analyser has 2 x USB ports for additional accessories e.g. barcode scanner, printer or USB for results export.

MultiSTAT Cartridge

The pre-filled reagent cartridge requires minimal additional preparation and contains all reagents required for the chemiluminescent reaction to take place.

There are two biochip wells for patient samples.

Evidence Multistat Clinical Biochips arrow_right_alt

Evidence Multistat Critical Care Biochips arrow_right_alt